{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:50:00Z","timestamp":1792698600109,"version":"4.5.0"},"reference-count":73,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Patients with chronic kidney disease (CKD) have a high incidence and prevalence of atrial fibrillation (AF). While general treatment strategies for AF may largely be transferred to patients with mild to moderate CKD, patients with advanced CKD\u2014particularly hemodialysis (HD) patients\u2014with AF pose substantial therapeutical challenges to cardiologists and nephrologists. The arguably greatest dilemma is the very limited evidence on appropriate strategies for prevention of stroke and systemic embolism in HD patients with AF, since the risk for both thromboembolic events without oral anticoagulation and severe bleeding events with oral anticoagulation are substantially increased in advanced CKD, compared with the general population. Thus, the benefit to risk ratio of either vitamin K antagonists or direct oral anticoagulants is less evident in HD than in non-CKD patients with AF.<\/jats:p>\n               <jats:p>As a multidisciplinary panel of clinicians, we here propose 10 tips that may help our colleagues to navigate between the risk of undertreatment\u2014exposing CKD patients with AF to a high stroke risk\u2014and overtreatment\u2014exposing the very same patients to a prohibitively high bleeding risk. These tips include ideas on alternative risk stratification strategies and novel treatment approaches that are currently in clinical studies\u2014such as factor XI inhibitors or left atrial appendage closure\u2014and may become game-changers for HD patients with AF.<\/jats:p>","DOI":"10.1093\/ckj\/sfae270","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T01:22:58Z","timestamp":1728091378000},"source":"Crossref","is-referenced-by-count":10,"title":["Ten tips to manage oral anticoagulation in hemodialysis patients with atrial fibrillation"],"prefix":"10.1093","volume":"17","author":[{"given":"Gunnar H","family":"Heine","sequence":"first","affiliation":[{"name":"Saarland University Medical Center , Internal Medicine IV, Department of Nephrology and Hypertension, Homburg ,","place":["Germany"]},{"name":"Agaplesion Markus Hospital, Medical Clinic II, Department of Nephrology and Hypertension , Frankfurt am Main,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Schneppe","sequence":"additional","affiliation":[{"name":"Saarland University Medical Center , Internal Medicine IV, Department of Nephrology and Hypertension, Homburg ,","place":["Germany"]},{"name":"Agaplesion Markus Hospital, Medical Clinic II, Department of Nephrology and Hypertension , Frankfurt am Main,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6192-1741","authenticated-orcid":false,"given":"Rupert","family":"Bauersachs","sequence":"additional","affiliation":[{"name":"Cardioangiologic Center Bethanien , CCB, Gef\u00e4\u00dfzentrum, Frankfurt am Main ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6442-246X","authenticated-orcid":false,"given":"Ingo","family":"Eitel","sequence":"additional","affiliation":[{"name":"University Hospital Schleswig-Holstein, University Heart Center L\u00fcbeck, Department of Cardiology, Angiology and Intensive Care Medicine , L\u00fcbeck ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9276-8380","authenticated-orcid":false,"given":"Brendon L","family":"Neuen","sequence":"additional","affiliation":[{"name":"University of New South Wales, Faculty of Medicine and Health, The George Institute for Global Health , Sydney ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian T","family":"Ruff","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan H","family":"Schirmer","sequence":"additional","affiliation":[{"name":"Kardiopraxis Schirmer, Am Altenhof 8 , Kaiserslautern ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9596-8529","authenticated-orcid":false,"given":"An","family":"De Vriese","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Infectious Diseases , AZ Sint-Jan Brugge, Brugge, , Ghent ,","place":["Belgium"]},{"name":"and Department of Internal Medicine, Ghent University , AZ Sint-Jan Brugge, Brugge, , Ghent ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"2024102217541552900_bib1","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"key":"2024102217541552900_bib2","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1681\/ASN.2019060579","article-title":"Multicenter randomized controlled trial of vitamin K antagonist replacement by rivaroxaban with or without vitamin K2 in hemodialysis patients with atrial fibrillation: the Valkyrie Study","volume":"31","author":"De Vriese","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2024102217541552900_bib3","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial","volume":"32","author":"De Vriese","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2024102217541552900_bib4","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"key":"2024102217541552900_bib5","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000250","article-title":"A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score","volume":"2","author":"Singer","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2024102217541552900_bib6","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.jacc.2015.08.033","article-title":"Comparative performance of ATRIA, CHADS2, and CHA2DS2-VASc risk scores predicting stroke in patients with atrial fibrillation","volume":"66","author":"van den Ham","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2024102217541552900_bib7","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/ndt\/gfab197","article-title":"Epidemiology, thrombolytic management, and outcomes of acute stroke among patients with chronic kidney disease: a systematic review and meta-analysis","volume":"37","author":"Zamberg","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2024102217541552900_bib8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/ki.2013.170","article-title":"Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: results from the DOPPS","volume":"84","author":"Sood","year":"2013","journal-title":"Kidney Int"},{"key":"2024102217541552900_bib9","doi-asserted-by":"publisher","DOI":"10.1177\/20543581231169610","article-title":"Development and validation of a predictive risk algorithm for bleeding in individuals on long-term hemodialysis: an international prospective cohort study (BLEED-HD)","volume":"10","author":"Madken","year":"2023","journal-title":"Can J Kidney Health Dis"},{"key":"2024102217541552900_bib10","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/europace\/euaa287","article-title":"Atrial fibrillation burden: an update\u2014the need for a CHA2DS2-VASc-AFBurden score","volume":"23","author":"Tiver","year":"2021","journal-title":"Europace"},{"key":"2024102217541552900_bib11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa1105575","article-title":"Subclinical atrial fibrillation and the risk of stroke","volume":"366","author":"Healey","year":"2012","journal-title":"N Engl J Med"},{"key":"2024102217541552900_bib12","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/eurheartj\/ehx042","article-title":"Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT","volume":"38","author":"Van Gelder","year":"2017","journal-title":"Eur Heart J"},{"key":"2024102217541552900_bib13","first-page":"140","article-title":"Subclinical and device-detected atrial fibrillation: pondering the knowledge gap: a scientific statement from the American Heart Association","author":"Noseworthy","year":"2019","journal-title":"Circulation"},{"key":"2024102217541552900_bib14","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1056\/NEJMoa2303062","article-title":"Anticoagulation with edoxaban in patients with atrial high-rate episodes","volume":"389","author":"Kirchhof","year":"2023","journal-title":"N Engl J Med"},{"key":"2024102217541552900_bib15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa2310234","article-title":"Apixaban for stroke prevention in subclinical atrial fibrillation","volume":"390","author":"Healey","year":"2024","journal-title":"N Engl J Med"},{"key":"2024102217541552900_bib16","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2024.06.038","article-title":"Time to benefit and harm of direct oral anticoagulants in device-detected atrial fibrillation: a pooled analysis of the NOAH-AFNET 6 and ARTESiA trials","author":"Huang","year":"2024","journal-title":"Heart Rhythm"},{"key":"2024102217541552900_bib17","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/heartjnl-2013-305417","article-title":"The dialysis procedure as a trigger for atrial fibrillation: new insights in the development of atrial fibrillation in dialysis patients","volume":"100","author":"Buiten","year":"2014","journal-title":"Heart"},{"key":"2024102217541552900_bib18","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/europace\/eut346","article-title":"Recurrent intradialytic paroxysmal atrial fibrillation: hypotheses on onset mechanisms based on clinical data and computational analysis","volume":"16","author":"Vincenti","year":"2014","journal-title":"Europace"},{"key":"2024102217541552900_bib19","first-page":"e1","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of atrial fibrillation: a report of the American College of Cardiology\/American Heart","volume-title":"Circulation","author":"Joglar","year":"2024"},{"key":"2024102217541552900_bib20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2024102217541552900_bib21","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1681\/ASN.2007111207","article-title":"Dilemmas in the management of atrial fibrillation in chronic kidney disease","volume":"20","author":"Reinecke","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2024102217541552900_bib22","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1161\/CIRCULATIONAHA.122.061647","article-title":"Apixaban compared with warfarin in patients with atrial fibrillation and end-stage renal disease: lessons learned","volume":"146","author":"Benz","year":"2022","journal-title":"Circulation"},{"key":"2024102217541552900_bib23","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"2024102217541552900_bib24","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"2024102217541552900_bib25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ahj.2016.09.016","article-title":"Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: a systematic review and meta-analysis","volume":"184","author":"Van Der Meersch","year":"2017","journal-title":"Am Heart J"},{"key":"2024102217541552900_bib26","doi-asserted-by":"publisher","first-page":"e019609","DOI":"10.1161\/JAHA.120.019609","article-title":"Non-vitamin K antagonist oral anticoagulants provide less adverse renal outcomes than warfarin in non-valvular atrial fibrillation: a systematic review and metaanalysis","volume":"10","author":"Sitticharoenchai","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2024102217541552900_bib27","doi-asserted-by":"crossref","first-page":"100813","DOI":"10.1016\/j.jacadv.2023.100813","article-title":"Rivaroxaban vs vitamin K antagonist in patients with atrial fibrillation and advanced chronic kidney disease","volume":"3","author":"Kreutz","year":"2024","journal-title":"JACC Adv"},{"key":"2024102217541552900_bib28","doi-asserted-by":"publisher","first-page":"938567","DOI":"10.3389\/fcvm.2022.938567","article-title":"Vitamin K antagonists and cardiovascular calcification: a systematic review and meta-analysis","volume":"9","author":"Kosciuszek","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2024102217541552900_bib29","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease\u2013associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N Engl J Med"},{"key":"2024102217541552900_bib30","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","article-title":"Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome","volume":"132","author":"Pengo","year":"2018","journal-title":"Blood"},{"key":"2024102217541552900_bib31","doi-asserted-by":"publisher","first-page":"685","DOI":"10.7326\/M19-0291","article-title":"Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome","volume":"171","author":"Ordi-Ros","year":"2019","journal-title":"Ann Intern Med"},{"key":"2024102217541552900_bib32","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1182\/bloodadvances.2021005808","article-title":"Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial","volume":"6","author":"Woller","year":"2022","journal-title":"Blood Adv"},{"key":"2024102217541552900_bib33","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1161\/CIRCULATIONAHA.122.062752","article-title":"Direct oral anticoagulants versus warfarin across the spectrum of kidney function: patient-level network meta-analyses from COMBINE AF","volume":"147","author":"Harrington","year":"2023","journal-title":"Circulation"},{"key":"2024102217541552900_bib34","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1053\/j.ajkd.2015.01.022","article-title":"Dose-finding study of rivaroxaban in hemodialysis patients","volume":"66","author":"De Vriese","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2024102217541552900_bib35","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1681\/ASN.2016090980","article-title":"Apixaban pharmacokinetics at steady state in hemodialysis patients","volume":"28","author":"Mavrakanas","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2024102217541552900_bib36","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1161\/CIRCULATIONAHA.123.065614","article-title":"Associations of apixaban dose with safety and effectiveness outcomes in patients with atrial fibrillation and severe chronic kidney disease","volume":"148","author":"Xu","year":"2023","journal-title":"Circulation"},{"key":"2024102217541552900_bib37","first-page":"CD011858","article-title":"Anticoagulation for people receiving long-term haemodialysis","volume":"1","author":"Natale","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2024102217541552900_bib38","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12882-017-0596-4","article-title":"Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis","volume":"18","author":"Lazrak","year":"2017","journal-title":"BMC Nephrol"},{"key":"2024102217541552900_bib39","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/j.1523-1755.2005.00468.x","article-title":"The effect of oral anticoagulation on clotting during hemodialysis","volume":"68","author":"Ziai","year":"2005","journal-title":"Kidney Int"},{"key":"2024102217541552900_bib40","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1159\/000118846","article-title":"Comparison of two dialysers (AN69ST vs. FX100) for heparin-free dialysis in patients with oral anticoagulation","volume":"26","author":"Kodras","year":"2008","journal-title":"Blood Purif"},{"key":"2024102217541552900_bib41","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1093\/ndt\/gft522","article-title":"Haemodialysis in patients treated with oral anticoagulant: should we heparinize?","volume":"29","author":"Krummel","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2024102217541552900_bib42","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1093\/ndt\/gfab060","article-title":"Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion","volume":"37","author":"De Vriese","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2024102217541552900_bib43","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2024102217541552900_bib44","doi-asserted-by":"publisher","first-page":"A7","DOI":"10.1053\/j.ajkd.2021.01.002","article-title":"US Renal Data System 2020 Annual Data Report: epidemiology of kidney disease in the United States","volume":"77","author":"Johansen","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2024102217541552900_bib45","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1053\/j.semvascsurg.2021.02.010","article-title":"Epidemiology of end-stage kidney disease","volume":"34","author":"Gupta","year":"2021","journal-title":"Semin Vasc Surg"},{"key":"2024102217541552900_bib46","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1093\/ndt\/gfx212","article-title":"Risk and complications of venous thromboembolism in dialysis patients","volume":"33","author":"Molnar","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2024102217541552900_bib47","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1016\/j.jacc.2019.02.048","article-title":"Rivaroxaban plus aspirin in patients with vascular disease and renal dysfunction","volume":"73","author":"Fox","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024102217541552900_bib48","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jacc.2021.06.021","article-title":"Rivaroxaban in patients with recent peripheral artery revascularization and renal impairment","volume":"78","author":"Hsia","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024102217541552900_bib49","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/ehjcvp\/pvab050","article-title":"Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial","volume":"8","author":"Vanassche","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024102217541552900_bib50","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet North Am Ed"},{"key":"2024102217541552900_bib51","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1016\/j.jacc.2015.04.025","article-title":"Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation","volume":"65","author":"Holmes","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2024102217541552900_bib52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy: the PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2024102217541552900_bib53","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1016\/j.jacc.2020.04.067","article-title":"Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation","volume":"75","author":"Osmancik","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2024102217541552900_bib54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2021.10.023","article-title":"4-Year outcomes after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation","volume":"79","author":"Osmancik","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2024102217541552900_bib55","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1056\/NEJMoa2101897","article-title":"Left atrial appendage occlusion during cardiac surgery to prevent stroke","volume":"384","author":"Whitlock","year":"2021","journal-title":"N Engl J Med"},{"key":"2024102217541552900_bib56","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/ccd.30559","article-title":"Left atrial appendage closure in end-stage renal disease and hemodialysis: data from a German multicenter registry","volume":"101","author":"Fink","year":"2023","journal-title":"Catheter Cardiovasc Interv"},{"key":"2024102217541552900_bib57","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1093\/ckj\/sfad221","article-title":"Long-term safety and efficacy of left atrial appendage occlusion in dialysis patients with atrial fibrillation: a multi-center, prospective, open label, observational study","volume":"16","author":"Genovesi","year":"2023","journal-title":"Clin Kidney J"},{"key":"2024102217541552900_bib58","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-023-02359-1","article-title":"Transcatheter left atrial appendage occlusion in patients with chronic kidney disease: a systematic review and meta-analysis","author":"Flores-Umanzor","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"2024102217541552900_bib59","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2024102217541552900_bib60","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"N Engl J Med"},{"key":"2024102217541552900_bib61","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1001\/jamacardio.2024.0133","article-title":"Ticagrelor or clopidogrel monotherapy vs dual antiplatelet therapy after percutaneous coronary intervention","volume":"9","author":"Valgimigli","year":"2024","journal-title":"JAMA Cardiol"},{"key":"2024102217541552900_bib62","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2215\/CJN.04100321","article-title":"Platelet abnormalities in CKD and their implications for antiplatelet therapy","volume":"17","author":"Baaten","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"2024102217541552900_bib63","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.kint.2021.08.028","article-title":"Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target","volume":"100","author":"Eikelboom","year":"2021","journal-title":"Kidney Int"},{"key":"2024102217541552900_bib64","doi-asserted-by":"publisher","first-page":"sfae106","DOI":"10.1093\/ckj\/sfae106","article-title":"Factor XI antagonists: the discovery of the philosopher's stone?","volume":"17","author":"De Vriese","year":"2024","journal-title":"Clin Kidney J"},{"key":"2024102217541552900_bib65","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41591-023-02794-7","article-title":"Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial","volume":"30","author":"Weitz","year":"2024","journal-title":"Nat Med"},{"key":"2024102217541552900_bib66","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.kint.2024.02.024","article-title":"A phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis","volume":"106","author":"Winkelmayer","year":"2024","journal-title":"Kidney Int"},{"key":"2024102217541552900_bib67","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","author":"Piccini","year":"2024","journal-title":"N Engl J Med"},{"key":"2024102217541552900_bib68","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41581-019-0212-x","article-title":"Kidney disease trials for the 21st century: innovations in design and conduct","volume":"16","author":"Herrington","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"2024102217541552900_bib69","doi-asserted-by":"publisher","first-page":"e240427","DOI":"10.1001\/jamanetworkopen.2024.0427","article-title":"Representation of patients with chronic kidney disease in clinical trials of cardiovascular disease medications","volume":"7","author":"Colombijn","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2024102217541552900_bib70","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1038\/ki.2009.477","article-title":"Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy","volume":"77","author":"Wizemann","year":"2010","journal-title":"Kidney Int"},{"key":"2024102217541552900_bib71","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.903029","article-title":"Factor XI inhibitors for prevention and treatment of venous thromboembolism: a review on the rationale and update on current evidence","volume":"9","author":"Nopp","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2024102217541552900_bib72","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","article-title":"Phase 2 study of the factor XI antisense inhibitor IONIS-FXIRx in patients with ESRD","volume":"7","author":"Walsh","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2024102217541552900_bib73","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1182\/blood.2021011725","article-title":"The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial","volume":"138","author":"Lorentz","year":"2021","journal-title":"Blood"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae270\/59597723\/sfae270.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae270\/59968841\/sfae270.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae270\/59968841\/sfae270.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T17:54:24Z","timestamp":1729619664000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae270\/7811318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":73,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae270","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,10,1]]},"article-number":"sfae270"}}